FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230491982> ?p ?o ?g. }

• W4230491982 abstract "Pulmonary sarcoidosis is a common condition with an unpredictable course. Oral or inhaled steroids are widely used in its treatment, but there is no consensus about when and in whom therapy should be initiated, what dose should be given and for how long. Corticosteroids given for several months have deleterious side-effects so it is important to know whether they have any maintained benefit in pulmonary sarcoidosis.To determine the randomised controlled trial (RCT) evidence for the benefit of corticosteroids (oral or inhaled) in the treatment of pulmonary sarcoidosis.The Cochrane Airways Group interstitial lung disease RCT register was searched using the terms: sarcoidosis and (steroid* OR corticosteroid* OR prednisolone OR prednisone OR beclomethasone OR budesonide OR fluticasone). Bibliographies of retrieved RCTs and reviews were searched for additional RCTs. Pharmaceutical companies and authors of identified RCTs were contacted for other published and unpublished studies.Two reviewers independently assessed full text articles for inclusion based upon the following criteria: the study had to be a RCT or controlled clinical trial in adults with histological evidence of pulmonary sarcoidosis.Study quality was assessed and data extracted independently by two reviewers. Outcomes were analysed as continuous and dichotomous outcomes, using standard statistical techniques.Eight RCTs were identified, two had insufficient data for any analysis. There were 338 patients in the four usable trials of oral steroids, and 66 patients in two trials of inhaled steroids. The oral steroid dose was equivalent to prednisolone 15-40 mg/day. The inhaled steroid was budesonide 0.8 - 1.2 mg/day. Outcomes were symptoms, chest X-ray (CXR) changes, lung function and global scores (a combination of all three outcomes). Oral steroids improved the CXR over 6-24 months. One study showed no improvement in lung function, in another there was an improvement in diffusing capacity in the treated group. Global scores improved in patients with stage 2 and 3 disease but not with stage 1 disease. There were no data on side-effects. Inhaled steroids had no effect on CXR. In one study diffusing capacity improved. In another, symptoms improved at the end of six months of treatment.Oral steroids improved the chest X-ray and a global score of CXR, symptoms and spirometry over 6-24 months. There is little evidence of an improvement in lung function. There are no data beyond 2 years to indicate whether oral steroids have any modifying effect on long-term disease progression. Oral steroids are indicated for patients with Stage 2 and 3 disease with moderate - severe or progressive symptoms or CXR changes. The available data provide no guidance for the management of this disease after 2 years. Short term (less than six months) of inhaled steroids may improved symptoms, perhaps in patients who mainly have cough." @default.
• W4230491982 created "2022-05-11" @default.
• W4230491982 creator A5050916400 @default.
• W4230491982 creator A5085360507 @default.
• W4230491982 date "2000-10-23" @default.
• W4230491982 modified "2023-10-03" @default.
• W4230491982 title "Corticosteroids for pulmonary sarcoidosis" @default.
• W4230491982 cites W1731493909 @default.
• W4230491982 cites W1924611011 @default.
• W4230491982 cites W1964494979 @default.
• W4230491982 cites W1974586332 @default.
• W4230491982 cites W1975506371 @default.
• W4230491982 cites W1984599209 @default.
• W4230491982 cites W1986215651 @default.
• W4230491982 cites W1987208829 @default.
• W4230491982 cites W1988497385 @default.
• W4230491982 cites W2011905555 @default.
• W4230491982 cites W2014792667 @default.
• W4230491982 cites W2042771149 @default.
• W4230491982 cites W2045013309 @default.
• W4230491982 cites W2052269157 @default.
• W4230491982 cites W2061106937 @default.
• W4230491982 cites W2081767660 @default.
• W4230491982 cites W2095667536 @default.
• W4230491982 cites W2096648253 @default.
• W4230491982 cites W2147469461 @default.
• W4230491982 cites W2162198836 @default.
• W4230491982 cites W2170815641 @default.
• W4230491982 cites W4214559180 @default.
• W4230491982 doi "https://doi.org/10.1002/14651858.cd001114" @default.
• W4230491982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10796598" @default.
• W4230491982 hasPublicationYear "2000" @default.
• W4230491982 type Work @default.
• W4230491982 citedByCount "9" @default.
• W4230491982 countsByYear W42304919822012 @default.
• W4230491982 countsByYear W42304919822013 @default.
• W4230491982 countsByYear W42304919822022 @default.
• W4230491982 countsByYear W42304919822023 @default.
• W4230491982 crossrefType "reference-entry" @default.
• W4230491982 hasAuthorship W4230491982A5050916400 @default.
• W4230491982 hasAuthorship W4230491982A5085360507 @default.
• W4230491982 hasConcept C126322002 @default.
• W4230491982 hasConcept C168563851 @default.
• W4230491982 hasConcept C2776042228 @default.
• W4230491982 hasConcept C2776136866 @default.
• W4230491982 hasConcept C2776478404 @default.
• W4230491982 hasConcept C2776715498 @default.
• W4230491982 hasConcept C2776804153 @default.
• W4230491982 hasConcept C2778720950 @default.
• W4230491982 hasConcept C2781301800 @default.
• W4230491982 hasConcept C71924100 @default.
• W4230491982 hasConceptScore W4230491982C126322002 @default.
• W4230491982 hasConceptScore W4230491982C168563851 @default.
• W4230491982 hasConceptScore W4230491982C2776042228 @default.
• W4230491982 hasConceptScore W4230491982C2776136866 @default.
• W4230491982 hasConceptScore W4230491982C2776478404 @default.
• W4230491982 hasConceptScore W4230491982C2776715498 @default.
• W4230491982 hasConceptScore W4230491982C2776804153 @default.
• W4230491982 hasConceptScore W4230491982C2778720950 @default.
• W4230491982 hasConceptScore W4230491982C2781301800 @default.
• W4230491982 hasConceptScore W4230491982C71924100 @default.
• W4230491982 hasLocation W42304919821 @default.
• W4230491982 hasLocation W42304919822 @default.
• W4230491982 hasOpenAccess W4230491982 @default.
• W4230491982 hasPrimaryLocation W42304919821 @default.
• W4230491982 hasRelatedWork W1982828640 @default.
• W4230491982 hasRelatedWork W2011474453 @default.
• W4230491982 hasRelatedWork W2057973646 @default.
• W4230491982 hasRelatedWork W2160731762 @default.
• W4230491982 hasRelatedWork W2342066803 @default.
• W4230491982 hasRelatedWork W2404861763 @default.
• W4230491982 hasRelatedWork W2418176843 @default.
• W4230491982 hasRelatedWork W2438744654 @default.
• W4230491982 hasRelatedWork W2440163331 @default.
• W4230491982 hasRelatedWork W4366505334 @default.
• W4230491982 isParatext "false" @default.
• W4230491982 isRetracted "false" @default.
• W4230491982 workType "reference-entry" @default.